Amgen Will Develop Predix S1P1 Modulators For Autoimmune Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will license preclinical S1P1 modulators from Predix for $20 mil. plus additional milestone payments up to $287.5 mil.
You may also be interested in...
Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”
Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”
Roche, Actelion To Develop S1P1 Receptor Agonist For Autoimmune Disease
Roche will pay Actelion $75 mil. up-front for co-development and co-marketing rights to the clinical program, now in Phase I.